CA2740056A1 - Methods and compositions for treating mammalian nerve tissue injuries - Google Patents

Methods and compositions for treating mammalian nerve tissue injuries Download PDF

Info

Publication number
CA2740056A1
CA2740056A1 CA2740056A CA2740056A CA2740056A1 CA 2740056 A1 CA2740056 A1 CA 2740056A1 CA 2740056 A CA2740056 A CA 2740056A CA 2740056 A CA2740056 A CA 2740056A CA 2740056 A1 CA2740056 A1 CA 2740056A1
Authority
CA
Canada
Prior art keywords
glycol
injury
fusion agent
peg
spinal cord
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2740056A
Other languages
English (en)
French (fr)
Inventor
Riyi Shi
Richard B. Borgens
Raphael C. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Purdue Research Foundation
Original Assignee
University of Chicago
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Purdue Research Foundation filed Critical University of Chicago
Publication of CA2740056A1 publication Critical patent/CA2740056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2740056A 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries Abandoned CA2740056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620001P 2001-04-24 2001-04-24
US60/286,200 2001-04-24
CA2445612A CA2445612C (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2445612A Division CA2445612C (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Publications (1)

Publication Number Publication Date
CA2740056A1 true CA2740056A1 (en) 2002-11-21

Family

ID=23097525

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2740056A Abandoned CA2740056A1 (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries
CA2445612A Expired - Fee Related CA2445612C (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2445612A Expired - Fee Related CA2445612C (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Country Status (9)

Country Link
US (4) US7837987B2 (enExample)
EP (1) EP1389121B1 (enExample)
JP (2) JP2004527573A (enExample)
AT (1) ATE546146T1 (enExample)
AU (2) AU2002314758B2 (enExample)
CA (2) CA2740056A1 (enExample)
ES (1) ES2382899T3 (enExample)
NZ (2) NZ543953A (enExample)
WO (1) WO2002092107A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
NZ543953A (en) * 2001-04-24 2007-04-27 Univ Chicago Method and compositions for treating mammalian nerve tissue injuries
US7147647B2 (en) 2002-04-26 2006-12-12 Medtronic, Inc. Sintered titanium tube for the management of spinal cord injury
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
EP1786454B1 (en) * 2004-08-19 2010-07-21 Biogen Idec MA Inc. Neublastin variants
DE602005022082D1 (de) * 2004-08-19 2010-08-12 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
US20060121016A1 (en) * 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
CN101084272B (zh) * 2004-12-21 2011-07-13 路博润有限公司 组合物
US20070048731A1 (en) * 2005-05-20 2007-03-01 Neurosilicon High throughput use-dependent assay based on stimulation of cells on a silicon surface
WO2006130599A2 (en) * 2005-05-31 2006-12-07 Warsaw Orthopedic, Inc. Compositions and methods for treating a damaged cardiovascular element
US20070017530A1 (en) * 2005-06-10 2007-01-25 Syed Naweed I Detecting electrical activity and assessing agents for the ability to influence electrical activity
US20060287660A1 (en) * 2005-06-15 2006-12-21 Syed Naweed I Electrically Stimulating Nerve Regeneration
US20060292549A1 (en) * 2005-06-15 2006-12-28 Neurosilicon Psychotropic drug screening device based on long-term photoconductive stimulation of neurons
JP4907908B2 (ja) * 2005-06-29 2012-04-04 ルネサスエレクトロニクス株式会社 駆動回路及び表示装置
US20070092958A1 (en) * 2005-07-15 2007-04-26 Syed Naweed I Method and apparatus for guiding growth of neurons
US20070213718A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Treatment of the vertebral column
US7520888B2 (en) * 2006-02-14 2009-04-21 Warsaw Orthopedic, Inc. Treatment of the vertebral column
US20070213717A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Biological fusion in the vertebral column
US20070227547A1 (en) * 2006-02-14 2007-10-04 Sdgi Holdings, Inc. Treatment of the vertebral column
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US9675696B2 (en) 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
US8329655B2 (en) 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
CA2744100C (en) * 2008-10-21 2020-06-30 The General Hospital Corporation Cell transplantation
US9244060B2 (en) * 2009-03-26 2016-01-26 Warsaw Orthopedic, Inc. Site localization and methods for monitoring treatment of disturbed blood vessels
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
US9078808B2 (en) * 2009-03-26 2015-07-14 Warsaw Orthopedic, Inc. Device to deliver magnesium in PEG formulation
US8852566B2 (en) 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
WO2010111212A1 (en) 2009-03-26 2010-09-30 Warsaw Orthopedic, Inc. Methods of identifying potential components for targeted drug delivery compositions
CA2758118C (en) 2009-04-07 2019-05-21 Catholic Healthcare West Uterine electrical stimulation system and method
US20110230785A1 (en) * 2010-03-16 2011-09-22 ProNerve, LLC Somatosensory Evoked Potential (SSEP) Automated Alert System
BR112013002859B1 (pt) 2010-08-06 2020-10-06 The General Hospital Corporation D/B/A Massachusetts General Hospital Método e aparelho para tratamento de células
CA3063888C (en) 2010-10-27 2020-12-22 Dignity Health Uterine electrical stimulation system and method
WO2013173833A1 (en) * 2012-05-18 2013-11-21 Dignity Health Electrical stimulation of the cervix
US9872983B2 (en) 2010-10-27 2018-01-23 Dignity Health Uterine electrical stimulation system and method
WO2012161823A1 (en) * 2011-02-25 2012-11-29 The General Hospital Corporation D/B/A Massachusetts General Hospital Nerve coaptation apparatus
EP2953640B1 (en) * 2013-02-07 2020-04-08 The Cleveland Clinic Foundation Nanoencapsulated superoxide dismutase and catalase for treating spinal cord injury
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
EP3658072B1 (en) 2017-07-26 2024-03-13 Neuraptive Therapeutics, Inc. Device for administering therapeutics to a nerve
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
JP7653164B2 (ja) * 2019-09-27 2025-03-28 バージニア コモンウェルス ユニバーシティー 組織を修復または増加させるための組成物および方法
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
WO2021150773A1 (en) * 2020-01-21 2021-07-29 The Penn State Research Foundation Methods and materials for treating nerve injury and/or promoting wound healing
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US20230190676A1 (en) * 2020-07-09 2023-06-22 Musc Foundation For Research Development Methods of protecting cells from insults
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
EP4387552A4 (en) 2021-08-18 2025-04-30 Augmedics Ltd. AUGMENTED REALITY SURGICAL SYSTEM USING DEPTH SENSING
WO2023203521A1 (en) 2022-04-21 2023-10-26 Augmedics Ltd. Systems and methods for medical image visualization
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369769A (en) 1980-06-13 1983-01-25 Edwards Charles C Spinal fixation device and method
US4599354A (en) 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US4919140A (en) 1988-10-14 1990-04-24 Purdue Research Foundation Method and apparatus for regenerating nerves
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
CA2075928A1 (en) * 1991-01-11 1992-07-12 Roger W. Hackett Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
CN1069741A (zh) 1991-03-19 1993-03-10 西特克斯公司 具有改进的生物活性的聚氧丙烯/聚氧乙烯共聚物
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5324322A (en) * 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
DE69322707T2 (de) 1992-07-31 1999-08-19 Bristol-Myers Squibb Company Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
CN1103698C (zh) * 1995-02-14 2003-03-26 东丽株式会社 平版印刷版及平板印刷版原版
JPH09315972A (ja) 1996-03-22 1997-12-09 Chugai Pharmaceut Co Ltd 脊髄損傷治療剤
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
EP1024812B1 (en) 1997-03-19 2007-01-24 Sky High, LLC Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US7582680B1 (en) * 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
AU4363600A (en) * 1999-04-22 2000-11-10 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury
NZ543953A (en) 2001-04-24 2007-04-27 Univ Chicago Method and compositions for treating mammalian nerve tissue injuries
US7199110B2 (en) 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury

Also Published As

Publication number Publication date
EP1389121A4 (en) 2006-11-02
US9687502B2 (en) 2017-06-27
CA2445612C (en) 2011-10-25
AU2006200866B2 (en) 2007-11-08
AU2006200866A1 (en) 2006-03-23
ATE546146T1 (de) 2012-03-15
EP1389121A1 (en) 2004-02-18
US20100016444A1 (en) 2010-01-21
NZ529526A (en) 2006-06-30
ES2382899T3 (es) 2012-06-14
WO2002092107A1 (en) 2002-11-21
US20030118545A1 (en) 2003-06-26
CA2445612A1 (en) 2002-11-21
US8460646B2 (en) 2013-06-11
US9101655B2 (en) 2015-08-11
EP1389121B1 (en) 2012-02-22
JP2009112835A (ja) 2009-05-28
US20140100289A1 (en) 2014-04-10
AU2002314758B2 (en) 2006-06-01
US20050069520A1 (en) 2005-03-31
US7837987B2 (en) 2010-11-23
NZ543953A (en) 2007-04-27
JP2004527573A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
CA2445612C (en) Methods and compositions for treating mammalian nerve tissue injuries
AU2002314758A1 (en) Method and composition for treating mammalian nerve tissue injuries
Somjen Mechanisms of spreading depression and hypoxic spreading depression-like depolarization
Shi et al. Functional reconnection of severed mammalian spinal cord axons with polyethylene glycol
Gomez-Amaya et al. Neural reconstruction methods of restoring bladder function
Collins et al. Structural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188
Borgens Cellular engineering: molecular repair of membranes to rescue cells of the damaged nervous system
EP0626848B1 (en) The use of 4-aminopyridine in the treatment of pain and spasticity resulting from spinal cord injury
Manto et al. (4-Aminopyridine)–PLGA–PEG as a Novel Thermosensitive and Locally Injectable Treatment for Acute Peripheral Nerve Injury
US7582680B1 (en) Methods and compositions for treating mammalian spinal cord injuries
Vale et al. Drugs and the Eye: Sponsored by the British Optical Association
DE69918541T2 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
Rotterman et al. Structural preservation does not ensure function at sensory Ia–motoneuron synapses following peripheral nerve injury and repair
Bitar Alatorre et al. Critical ischemia time in a model of spinal cord section. A study performed on dogs
Adnyana et al. A simple method to stimulate ischemic stroke in Wistar rat for animal testing
Seitz et al. Toxic effects of triethyldodecylammoniumbromide (TEA-C12) on myelinated nerve fibers and blood-nerve barrier in the mouse
Añor Monoparesis
Francis et al. Benzalkonium Chloride–Induced Denervation of Orbicularis Oculi Muscle in Rabbits
Hayashi et al. The electromyographic examination to evaluate the external sphincter muscle in anorectal malformations
Fox et al. The effect of angiography on the electrophysiological state of the spinal cord: a study in control and traumatized cats
US20200352923A1 (en) Treatment of side effects of botulinum therapies
Soto Critical ischemia time in a model of spinal cord section. A study performed on dogs
Borgens Recovery of Behavioral and Physiological Function In Vivo
Cormier The role of bulbospinal serotonergic axons in the regulation of blood pressure during noxious stimulation.
Gopinathan requirement for the degree of

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130524